Compare MCI & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | CGC |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 389.2M |
| IPO Year | N/A | 2023 |
| Metric | MCI | CGC |
|---|---|---|
| Price | $19.14 | $0.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | $10.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.21 | $0.84 |
| 52 Week High | $22.11 | $2.38 |
| Indicator | MCI | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 42.66 |
| Support Level | $17.38 | $0.91 |
| Resistance Level | $19.93 | $1.15 |
| Average True Range (ATR) | 0.56 | 0.03 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 39.51 | 23.17 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.